348 related articles for article (PubMed ID: 11384099)
1. Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients.
Scorilas A; Karameris A; Arnogiannaki N; Ardavanis A; Bassilopoulos P; Trangas T; Talieri M
Br J Cancer; 2001 Jun; 84(11):1488-96. PubMed ID: 11384099
[TBL] [Abstract][Full Text] [Related]
2. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994
[TBL] [Abstract][Full Text] [Related]
3. Polyadenylate polymerase enzymatic activity in mammary tumor cytosols: A new independent prognostic marker in primary breast cancer.
Scorilas A; Talieri M; Ardavanis A; Courtis N; Dimitriadis E; Yotis J; Tsiapalis CM; Trangas T
Cancer Res; 2000 Oct; 60(19):5427-33. PubMed ID: 11034084
[TBL] [Abstract][Full Text] [Related]
4. Immunoenzymatically determined pepsinogen C concentration in breast tumor cytosols: an independent favorable prognostic factor in node-positive patients.
Scorilas A; Diamandis EP; Levesque MA; Papanastasiou-Diamandi A; Khosravi MJ; Giai M; Ponzone R; Roagna R; Sismondi P; López-Otin C
Clin Cancer Res; 1999 Jul; 5(7):1778-85. PubMed ID: 10430082
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
6. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
[TBL] [Abstract][Full Text] [Related]
7. Expression of E-cadherin, beta-catenin, cathepsin D, gelatinases and their inhibitors in invasive ductal breast carcinomas.
Zhang YG; DU J; Tian XX; Zhong YF; Fang WG
Chin Med J (Engl); 2007 Sep; 120(18):1597-605. PubMed ID: 17908479
[TBL] [Abstract][Full Text] [Related]
8. Treatment results and prognostic factors of early breast cancer treated with a breast conserving operation and radiotherapy.
Kim KJ; Huh SJ; Yang JH; Park W; Nam SJ; Kim JH; Lee JH; Kang SS; Lee JE; Kang MK; Park YJ; Nam HR
Jpn J Clin Oncol; 2005 Mar; 35(3):126-33. PubMed ID: 15741302
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of matrix metalloproteinase 2 and 9 in breast cancer.
Shah FD; Shukla SN; Shah PM; Shukla HK; Patel PS
Indian J Cancer; 2009; 46(3):194-202. PubMed ID: 19574670
[TBL] [Abstract][Full Text] [Related]
10. [Zymography--method for quantitation of activity on gelatinase A (pro-MMP-2, 72 kDa) and gelatinase B (pro-MMP-9, 92 kDa) in serum of patients with breast cancer].
Sliwowska I; Kopczyński Z
Wiad Lek; 2007; 60(5-6):241-7. PubMed ID: 17966888
[TBL] [Abstract][Full Text] [Related]
11. High MMP-1 mRNA expression is a risk factor for disease-free and overall survivals in patients with invasive breast carcinoma.
Cheng S; Tada M; Hida Y; Asano T; Kuramae T; Takemoto N; Hamada J; Miyamoto M; Hirano S; Kondo S; Moriuchi T
J Surg Res; 2008 May; 146(1):104-9. PubMed ID: 17663001
[TBL] [Abstract][Full Text] [Related]
12. Clodronate treatment influences MMP-2 associated outcome in node positive breast cancer.
Leppä S; Saarto T; Vehmanen L; Blomqvist C; Elomaa I
Breast Cancer Res Treat; 2005 Mar; 90(2):117-25. PubMed ID: 15803358
[TBL] [Abstract][Full Text] [Related]
13. Gelatinase B expression as a prognostic factor in patients with stage II/III rectal carcinoma treated by postoperative adjuvant therapy.
Unsal D; Akyurek N; Uner A; Erpolat OP; Han U; Akmansu M; Mentes BB; Dursun A
Am J Clin Oncol; 2008 Feb; 31(1):55-63. PubMed ID: 18376229
[TBL] [Abstract][Full Text] [Related]
14. The clinicopathological and prognostic significance of membrane type 1 matrix metalloproteinase (MT1-MMP) and MMP-9 according to their localization in invasive breast carcinoma.
Mylona E; Nomikos A; Magkou C; Kamberou M; Papassideri I; Keramopoulos A; Nakopoulou L
Histopathology; 2007 Feb; 50(3):338-47. PubMed ID: 17257129
[TBL] [Abstract][Full Text] [Related]
15. [Expression and clinical significance of MMP-2, MMP-9,TIMP-1, and TIMP-2 in breast carcinoma].
Fan SQ; Wei QY; Li MR; Zhang LQ; Liang QC
Ai Zheng; 2003 Sep; 22(9):968-73. PubMed ID: 12969531
[TBL] [Abstract][Full Text] [Related]
16. Preoperative serum MMP-9 immunoreactive protein is a prognostic indicator for relapse-free survival in breast carcinoma.
Talvensaari-Mattila A; Turpeenniemi-Hujanen T
Cancer Lett; 2005 Jan; 217(2):237-42. PubMed ID: 15617842
[TBL] [Abstract][Full Text] [Related]
17. Prognostic markers in node-negative breast cancer: a prospective study.
Kute TE; Russell GB; Zbieranski N; Long R; Johnston S; Williams H; Stackhouse C; Wilkins L; Evans I; Berry P; Rimmer K; Tucker E
Cytometry B Clin Cytom; 2004 May; 59(1):24-31. PubMed ID: 15108167
[TBL] [Abstract][Full Text] [Related]
18. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer.
Lengyel E; Schmalfeldt B; Konik E; Späthe K; Härting K; Fenn A; Berger U; Fridman R; Schmitt M; Prechtel D; Kuhn W
Gynecol Oncol; 2001 Aug; 82(2):291-8. PubMed ID: 11531282
[TBL] [Abstract][Full Text] [Related]
19. Lymphovascular invasion is associated with reduced locoregional control and survival in women with node-negative breast cancer treated with mastectomy and systemic therapy.
Truong PT; Yong CM; Abnousi F; Lee J; Kader HA; Hayashi A; Olivotto IA
J Am Coll Surg; 2005 Jun; 200(6):912-21. PubMed ID: 15922205
[TBL] [Abstract][Full Text] [Related]
20. RECK expression in pancreatic cancer: its correlation with lower invasiveness and better prognosis.
Masui T; Doi R; Koshiba T; Fujimoto K; Tsuji S; Nakajima S; Koizumi M; Toyoda E; Tulachan S; Ito D; Kami K; Mori T; Wada M; Noda M; Imamura M
Clin Cancer Res; 2003 May; 9(5):1779-84. PubMed ID: 12738734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
